论文部分内容阅读
[目的]比较FOLFIRI方案与FOLFOX4方案一线治疗晚期大肠癌的疗效和不良反应。[方法]将56例晚期大肠癌患者随机分为两组:FOLFIRI方案组(n=28)和FOLFOX4方案组(n=28),2个周期后观察疗效和不良反应。[结果]FOLFIRI组有效率(RR)为35.7%,中位肿瘤进展时间(TTP)为7.5个月,中位总生存期(mOS)为15个月,1、2、3年生存率分别为89.29%、73.08%和40.00%;FOLFOX4组RR为39.3%,TTP为7.5个月,mOS为16个月,1、2、3年生存率分别为89.29%、72.00%和45.45%;两组比较各项指标差异无统计学意义(P>0.05)。不良反应中FOLFIRI组腹泻发生率高于FOLFOX4组,神经毒性发生率明显低于FOLFOX4组。[结论]FOLFIRI方案与FOLFOX4方案的疗效相当,都可作为晚期大肠癌的一线标准方案。
[Objective] To compare the efficacy and adverse reactions of FOLFIRI and FOLFOX4 in the first-line treatment of advanced colorectal cancer. [Methods] 56 patients with advanced colorectal cancer were randomly divided into two groups: FOLFIRI regimen group (n=28) and FOLFOX4 regimen group (n=28). The curative effect and adverse reactions were observed after 2 cycles. [Results] The effective rate (RR) was 35.7% in the FOLFIRI group, the median tumor progression time (TTP) was 7.5 months, the median overall survival (mOS) was 15 months, and the 1-, 2-, and 3-year survival rates were 89.29%, 73.08% and 40.00%; the RR in the FOLFOX4 group was 39.3%, the TTP was 7.5 months, the mOS was 16 months, and the 1-, 2-, and 3-year survival rates were 89.29%, 72.00%, and 45.45%, respectively; There was no significant difference in various indicators (P>0.05). The incidence of diarrhea in the FOLFIRI group was higher than that in the FOLFOX4 group. The incidence of neurotoxicity was significantly lower in the FOLFIRI group than in the FOLFOX4 group. [Conclusions] The efficacy of FOLFIRI is similar to that of FOLFOX4 and can be used as the first-line standard for advanced colorectal cancer.